IUdR/BUdR Cell Cycle Labelling
Information source: M.D. Anderson Cancer Center
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hematologic Malignancies
Intervention: Chemotherapy for hematologic malignancy (Drug)
Phase: N/A
Status: Terminated
Sponsored by: M.D. Anderson Cancer Center Official(s) and/or principal investigator(s):
Michael Andreeff, MD, PhD, Study Chair, Affiliation: U. T. M. D. Anderson Cancer Center
Summary
To determine cell cycle parameters and changes after treatment, the labelling agent is given
and a bone marrow aspiration is accomplished before treatment and after treatment for
comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.
Clinical Details
Official title: Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling
Study design: Diagnostic, Non-Randomized, Open Label, Single Group Assignment, Pharmacodynamics Study
Detailed description:
Cell cycle parameters include LI, Ts, Tc, T dpot, changes in these parameters, and
differences between normal and leukemic cells in patients with hematologic malignancy prior
to and following treatment.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Histologic proof of one of:
- AML, ALL, or AUL
- MDS or CMML
- CML
- OR undergoing bone marrow transplantation.
Participants should be:
- off therapy for at least two weeks
- At least 18 years old or older
- Using adequate contraception if of child-bearing capability.
Locations and Contacts
M.D. Anderson Cancer Center, Houston, Texas 77030, United States
Additional Information
M. D. Anderson Cancer Center
Starting date: October 1991
Last updated: June 23, 2005
|
